Future directions for unsealed source radionuclide therapy for bone metastases
- 16 August 2002
- journal article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 29 (10) , 1271-1275
- https://doi.org/10.1007/s00259-002-0914-2
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone MetastasesJournal of Clinical Oncology, 2002
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- Selective accumulation of strontium-89 in metastatic deposits in boneNuclear Medicine Communications, 1995
- A direct measurement of strontium-89 activity in bone metastasesNuclear Medicine Communications, 1995
- Targeting Radiation to TumoursInternational Journal of Radiation Biology, 1994
- A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonateEuropean Journal of Cancer and Clinical Oncology, 1991
- A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to boneEuropean Journal of Cancer and Clinical Oncology, 1991
- Phosphorus-32 for intractable bony pain from carcinoma of the prostateClinical Oncology, 1990
- Importance of effective pain controlActa Anaesthesiologica Scandinavica, 1987
- The flare phenomenon on radionuclide bone scan in metastatic prostate cancerAmerican Journal of Roentgenology, 1984